{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-054758","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.988584+00:00","generated_at":"2026-06-13T12:44:13.069536+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Longeveron appoints Dr. Nataliya Agafonova as CMO, effective July 1, 2023","bullets":["Dr. Agafonova replaces Dr. K. Chris Min, who stepped down as CMO on June 30, 2023.","She will lead global clinical development and regulatory strategy.","Agafonova previously served as Clinical Development Lead at Otsuka Pharmaceutical and Bristol-Myers Squibb.","A consulting agreement with hourly cash fee is in place until full-time employment begins on or about July 24, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-054758","json":"https://secwatch.observer/filing/0001213900-23-054758.json","markdown":"https://secwatch.observer/filing/0001213900-23-054758.md","text":"https://secwatch.observer/filing/0001213900-23-054758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/0001213900-23-054758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/ea181311-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:44:13.069536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49a83b7eb4","claim":"K. Chris Min departed as Chief Medical Officer at Longeveron Inc..","evidence_excerpt":"Dr. K. Chris Min, the Company’s prior CMO, stepped down effective June 30, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/0001213900-23-054758-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"f87ca27a9a","claim":"Nataliya Agafonova was appointed as Chief Medical Officer at Longeveron Inc..","evidence_excerpt":"Longeveron Inc. (“Longeveron” or the “Company”) has announced the appointment of Dr. Nataliya Agafonova M.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (“CMO”), effective July 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/0001213900-23-054758-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}